'Resting' exhausted cancer-fighting immune cells enhances their tumor-killing activity, which may help people with blood and solid cancers.
A Stanford-developed anti-cancer therapy currently in clinical trials may also reduce vascular inflammation in heart disease.
Stanford scientists have taken important steps toward figuring out how to use immune therapy for a group of severe pediatric brain tumors.
Pioneering immunotherapy drug Provenge is enjoying a revival, thanks to a large new clinical trial that will test it in men with early prostate cancer.
Scientists have made an important step forward in treating a deadly childhood brain tumor, using T cells engineered to target a surface sugar found on the cancer cells.
Stanford researchers led work on a possible cancer vaccine that involves injecting two immune-stimulating agents directly into solid tumors.
